Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
School of Life Sciences, Central South University, Changsha, Hunan, China.
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620981863. doi: 10.1177/1753466620981863.
It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma.
Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted according to the standard criteria. Stata 14.0 software was used to analyze the diagnostic value of microRNA for asthma, including the combined sensitivity (Sen), specificity (Spe), the area under the curve (AUC), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR).
A total of 72 studies, containing 4143 cases and 2188 controls, were included for this comprehensive analysis. None of the included publications were rated low in quality. We summarized that, compared with controls, more than 100 miRNAs were reported differently expressed in asthma, although the expression trends were inconsistent. Besides, there were five studies among these 72 articles that applied the diagnostic evaluation of microRNAs in asthma. We found that the pooled Sen, Spe, and AUC for the combination of miR-185-5p, miR-155, let-7a, miR-21, miR-320a, miR-1246, miR-144-5p, and miR-1165-3p in asthma were 0.87 (95%CI: 0.72-0.95), 0.84 (95%CI: 0.74-0.91), and 0.93 (95%CI: 0.89-0.94) individually, and the PLR, NLR, and DOR were 5.5 (95%CI: 3.1-9.7), 0.15 (95%CI: 0.07-0.36), and 35 (95%CI: 10-127) in asthma, respectively. In terms of subgroup analyses, we found that the Sen for these combination miRNAs from serum was higher than that in plasma, while the Spe in plasma worked better than that in serum. Furthermore, compared with children, the combination of above miRNAs from adults had higher Spe and similar Sen.
From our analysis, the combination of miR-185-5p, miR-155, let-7a, miR-21, miR-320a, miR-1246, miR-144-5p, and miR-1165-3p from peripheral blood could potentially act as a diagnostic biomarker for asthma.
目前尚不清楚 microRNAs 是否可以作为哮喘的潜在诊断生物标志物。本研究旨在探讨 microRNAs 在哮喘中的诊断价值。
根据标准标准，进行文献检索、出版物筛选、特定数据提取和质量评估。Stata 14.0 软件用于分析 microRNA 对哮喘的诊断价值，包括合并敏感度（Sen）、特异度（Spe）、曲线下面积（AUC）、阳性似然比（PLR）、阴性似然比（NLR）和诊断比值比（DOR）。
共有 72 项研究，包含 4143 例病例和 2188 例对照，被纳入本综合分析。纳入的文献均未被评为低质量。我们总结发现，与对照组相比，100 多种 microRNAs 在哮喘中报告表达不同，尽管表达趋势不一致。此外，在这 72 篇文章中有 5 篇研究应用了 microRNAs 在哮喘中的诊断评估。我们发现，miR-185-5p、miR-155、let-7a、miR-21、miR-320a、miR-1246、miR-144-5p 和 miR-1165-3p 在哮喘中的合并 Sen、Spe 和 AUC 分别为 0.87（95%CI：0.72-0.95）、0.84（95%CI：0.74-0.91）和 0.93（95%CI：0.89-0.94），PLR、NLR 和 DOR 分别为 5.5（95%CI：3.1-9.7）、0.15（95%CI：0.07-0.36）和 35（95%CI：10-127）。在亚组分析中，我们发现这些来自血清的组合 microRNAs 的 Sen 高于血浆中的 Sen，而血浆中的 Spe 优于血清中的 Spe。此外，与儿童相比，来自成年人的上述 microRNAs 的组合具有更高的 Spe 和相似的 Sen。
根据我们的分析，来自外周血的 miR-185-5p、miR-155、let-7a、miR-21、miR-320a、miR-1246、miR-144-5p 和 miR-1165-3p 的组合可能作为哮喘的诊断生物标志物。
